# US 2004/0019015 A1 · Protection against and treatment of hearing loss

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0019015 A1
- Document ID: US20040019015A1
- Status: Published application
- Kind: A1
- Application number: 10/277,220
- Filed: 2002-10-19
- Published: 2004-01-29
- Earliest claimed: 2001-10-22
- Assignees: The Research Foundation of State University of New York; Health Research, Inc. (Roswell Park Division)
- Inventors: Thomas Nicotera; Donald Henderson; David G. Hangauer JR.
- Web page: https://patentgrep.com/patent/US20040019015A1

## CPC

- C07D 209/04: Indoles; Hydrogenated indoles
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/47: Quinolines; Isoquinolines
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/16: Otologicals
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method for protecting against or treating hearing loss in a subject. This method involves administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss.

## Claims

### Claim 1

A method for protecting against or treating hearing loss in a subject comprising administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the protein tyrosine kinase inhibitor is a non-peptide protein tyrosine kinase inhibitor.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the non-peptide protein tyrosine kinase inhibitor comprises at least one first module having one or more functional groups each capable of covalently or non-covalently binding to catalytic residues of the protein kinase and a second module which provides a non-peptide scaffold, wherein the combination of the at least one first module and second module inhibits protein kinase activity.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the at least one first module comprises two or more functional groups.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the at least one first module comprises a functional group selected from the group consisting of a halogen, a boronic acid, a hydroxyl group, phosphonic acid, sulfamic acid, a guanidino group, carboxylic acid, an aldehyde, an amide, and hydroxymethylphosphonic acid.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the at least one first module comprises a halogen.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the at least one first module comprises a boronic acid group.

### Claim at position 8 (depends on 5)

8 The method according to claim 5, wherein the at least one first module comprises a hydroxyl group.

### Claim 9 (depends on 5)

The method according to claim 5, wherein the at least one first module comprises an amide group.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the amide group is a vicinal tricarbonyl amide.

### Claim 11 (depends on 3)

The method according to claim 3, wherein the second module comprises a group selected from the group consisting of indole, naphthalene, biphenyl, isoquinoline, benzofuran, and benzothiophene.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the second module comprises an indole.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the second module comprises naphthalene.

### Claim 14 (depends on 3)

The method according to claim 3, wherein the at least one first module further comprises a linear chain comprising between one and three carbon atoms which links the at least one first module to the second module.

### Claim 15 (depends on 14)

The method according to claim 14, wherein one of the carbon atoms in the linear chain is substituted with a nitrogen, oxygen, or sulfur atom.

### Claim 16 (depends on 3)

The method according to claim 3, wherein the non-peptide protein kinase inhibitor comprises one or more specificity side chain elements attached to the combination of the at least one first module and second module.

### Claim 17 (depends on 3)

The method according to claim 3, wherein the non-peptide protein tyrosine kinase inhibitor has the formula:
369
wherein R1 through R7 may be the same or different, and are selected from the group consisting of H. C(O)Ra, C(O)NRaRb, C(O)ORa, C(O)SRa, OH, ORa, OC(O)Ra, OC(O)ORa, NH2, NRaRb, NRaC(O)Rb, NRaC(O)NRbRc, NRaC(O)ORb, NRaC(O)SRb, NRaS(O)Rb, NRaS(O)2Rb, NRaS(O)ORb, NRaS(O)2ORb, NRaP(O)ORbORc, NRaP(O)ORbRc, NRaP(O)ORbORc, SRa, S(O)Ra, S(O)2Ra, S(O)ORa, S(O)2ORa, S(O)NRaRb, S(O)2NRaRb, P(O)ORaORb, B(OH)2, halogen, aryl, heteroaryl, biaryl, heterobiaryl, heterocyclic compound, and branched, cyclic, or unbranched alkyl,
wherein Ra, Rb, and Rc may be the same or different and are selected from the group consisting of H, aryl, heteroaryl, biaryl, heterobiaryl, and branched, cyclic, or unbranched alkyl; or
R5 and R6 together form a heterocyclic compound; and
wherein any of R1 through R7 and Ra through Rc is substituted or unsubstituted.

### Claim 18 (depends on 17)

The method according to claim 17, wherein R3 is a halogen.

### Claim 19 (depends on 18)

The method according to claim 18, wherein R3 is fluorine.

### Claim 20 (depends on 17)

The method according to claim 17, wherein at least one of R6 or R7 is
370
wherein R8* is the point of attachment and is (CH2)x, wherein X is from 0 to 10, CH2CHOH, CH(CH3)R, or CH(CH3)S, and each of R9 through R13 may be the same or different, and are selected from the group consisting of H, C(O)Ra, C(O)NRaRb, C(O)ORa, C(O)SRa, OH, ORa, OC(O)Ra, OC(O)ORa, NH2, NRaRb, NRaC(O)Rb, NRaC(O)NRbRc, NRaC(O)ORb, NRaC(O)SRb, NRaS(O)Rb, NRaS(O)2Rb, NRaS(O)ORb, NRaS(O)2ORb, NRaP(O)ORbORc, NRaP(O)ORbRc, NRaP(O)ORbORc, SRa, S(O)Ra, S(O)2Ra, S(O)ORa, S(O)2ORa, S(O)NRaRb, S(O)2NRaRb, P(O)ORaORb, B(OH)2, halogen, aryl, heteroaryl, biaryl, heterobiaryl, heterocyclic compound, and branched, cyclic, or unbranched alkyl,
wherein Ra, Rb, and Rc may be the same or different and are selected from the group consisting of H, aryl, heteroaryl, biaryl, heterobiaryl, and branched, cyclic, or unbranched alkyl; and
wherein any of R9 through R13 and Ra through Rc is substituted or unsubstituted.

### Claim 21 (depends on 17)

The method according to claim 17, wherein at least one of R6 or R7 is
371
wherein the asterisk indicates the point of attachment to the nitrogen.

### Claim 22 (depends on 3)

The method according to claim 3, wherein the non-peptide tyrosine kinase inhibitor has the formula:
372
wherein X is a halogen, R1 is H, R2 is
373
R3 is H, and R4 is H.

### Claim 23 (depends on 22)

The method according to claim 22, wherein X is fluorine.

### Claim 24 (depends on 3)

The method according to claim 3, wherein the non-peptide tyrosine kinase inhibitor has the formula
374
wherein R1 through R7 may be the same or different, and are selected from the group consisting of H, C(O)Ra, C(O)NRaRb, C(O)ORa, C(O)SRa, OH, ORa, OC(O)Ra, OC(O)ORa, NH2, NRaRb, NRaC(O)Rb, NRaC(O)NRbRc, NRaC(O)ORb, NRaC(O)SRb, NRaS(O)Rb, NRaS(O)2Rb, NRaS(O)ORb, NRaS(O)2ORb, NRaP(O)ORbORc, NRaP(O)ORbRc, NRaP(O)ORbORc, SRa, S(O)Ra, S(O)2Ra, S(O)ORa, S(O)2ORa, S(O)NRaRb, S(O)2NRaRb, P(O)ORaORb, B(OH)2, halogen, aryl, heteroaryl, biaryl, heterobiaryl, heterocyclic compound, and branched, cyclic, or unbranched alkyl,
wherein Ra, Rb, and Rc may be the same or different and are selected from the group consisting of H, aryl, heteroaryl, biaryl, heterobiaryl, and branched, cyclic, or unbranched alkyl;
wherein any of R1 through R7 and Ra through Rc is substituted or unsubstituted; and
wherein X is 0 or 1.

### Claim 25 (depends on 1)

The method according to claim 1, wherein the protein tyrosine kinase inhibitor is a peptide protein tyrosine kinase inhibitor.

### Claim 26 (depends on 1)

The method according to claim 1, wherein the protein tyrosine kinase inhibitor inhibits protein tyrosine kinase activity but does not inhibit ATP binding to the protein tyrosine kinase.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the protein tyrosine kinase inhibitor is a peptide substrate directed inhibitor.

### Claim 28 (depends on 1)

The method according to claim 1, wherein the protein tyrosine kinase inhibitor is a SH2 inhibitor.

### Claim 29 (depends on 1)

The method according to claim 1, wherein the protein tyrosine kinase inhibitor is a SH3 inhibitor.

### Claim 30 (depends on 1)

The method according to claim 1, wherein the protein tyrosine kinase inhibitor is an allosteric inhibitor.

### Claim 31 (depends on 1)

The method according to claim 1, wherein the protein tyrosine kinase inhibitor inhibits ATP binding to the protein tyrosine kinase.

### Claim 32 (depends on 1)

The method according to claim 1, wherein the protein tyrosine kinase is a Src family protein tyrosine kinase.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the Src family protein tyrosine kinase is pp60c-src tyrosine kinase.

### Claim 34 (depends on 1)

The method according to claim 1, wherein the protein tyrosine kinase is focal adhesion kinase.

### Claim 35 (depends on 1)

The method according to claim 1, wherein the administering is carried out orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitary or intravesical instillation, intraauditorily, intraarterially, intralesionally, by metering pump, or by application to mucous membranes.

### Claim 36 (depends on 1)

The method according to claim 1, wherein protein tyrosine kinase inhibitor is administered with a pharmaceutically acceptable carrier.

### Claim 37 (depends on 1)

The method according to claim 1, wherein the protein tyrosine kinase inhibitor is administered before initiation of hearing loss.

### Claim 38 (depends on 1)

The method according to claim 1, wherein the protein tyrosine kinase inhibitor is administered after initiation of hearing loss.
